What question did this study set out to answer?

To evaluate the efficacy and safety of quetiapine in patients with schizophrenia spectrum disorders and comorbid substance use disorders.

March 7, 2026PharmaceuticalsOpen Access

Preliminary Evidence on the Efficacy and Tolerability of Quetiapine in Dual Disorders: A Prospective, Multicentric, Real-World Study

View Full Paper

Ask AI

Bookmark

Authors

Prospective study shows quetiapine improves psychopathology in individuals with dual disorders, implying its therapeutic potential.

To evaluate the efficacy and safety of quetiapine in patients with schizophrenia spectrum disorders and comorbid substance use disorders.
Conducted a multicentric, prospective study
Included 28 participants with schizophrenia spectrum disorder and comorbid substance use disorder
Administered quetiapine at a mean dosage of 165 mg/day
Performed psychometric evaluations at baseline, one month, and three months post-initiation of treatment
Measured psychopathological burden, aggressivity, substance craving, and quality of life
Quetiapine significantly reduced psychopathological symptoms as shown by decreased PANSS total scores (p < 0.001)
Positive symptoms significantly improved (p < 0.001)
Negative symptoms decreased (p = 0.002)
Substance craving showed notable reduction (p = 0.001)
Quality of life scores significantly improved (p < 0.001)

Mosca et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark